Saudi Central Bank Buys 5,593 Shares of IQVIA Holdings Inc. $IQV

Key Points

• Saudi Central Bank increased its IQVIA stake by 89% in the second quarter, acquiring 5,593 shares and bringing its holdings to 11,879 shares valued at approximately $2.3 million. Institutional investors collectively own 89.62% of the company.
• Analysts remain broadly positive, with IQVIA carrying a consensus rating of “Moderate Buy” and an average price target of $243.62. JPMorgan, BMO Capital Markets and RBC recently raised their targets, while Morgan Stanley maintained an equal-weight rating.
• IQVIA beat quarterly expectations with EPS of $3.15 versus $3.03 expected and revenue of $4.37 billion, up 8.7% year over year. Shares opened at $267.34, near the company’s 52-week high of $271.80, while insiders have sold $3.8 million of stock over the past 90 days.

Saudi Central Bank raised its stake in IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 89.0% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 11,879 shares of the medical research company's stock after acquiring an additional 5,593 shares during the period. Saudi Central Bank's holdings in IQVIA were worth $2,295,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Korea Investment CORP bought a new position in shares of IQVIA in the second quarter valued at approximately $13,918,000. Deutsche Bank AG acquired a new stake in IQVIA during the 2nd quarter valued at $143,074,000. BlackRock Inc. bought a new position in IQVIA in the 2nd quarter valued at $2,811,292,000. Focus Partners Advisor Solutions LLC bought a new position in IQVIA in the 2nd quarter valued at $976,000. Finally, Pallas Capital Advisors LLC acquired a new position in IQVIA in the second quarter worth $1,552,000. 89.62% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on IQV. BMO Capital Markets raised their target price on IQVIA from $210.00 to $270.00 and gave the company an "outperform" rating in a research note on Wednesday, July 29th. Weiss Ratings raised shares of IQVIA from a "hold (c-)" rating to a "hold (c)" rating in a report on Wednesday, July 15th. Morgan Stanley restated an "equal weight" rating and issued a $200.00 price objective (down from $225.00) on shares of IQVIA in a research report on Wednesday, June 17th. Royal Bank Of Canada upped their target price on shares of IQVIA from $221.00 to $247.00 and gave the stock an "outperform" rating in a research report on Wednesday, July 29th. Finally, JPMorgan Chase & Co. raised their price target on shares of IQVIA from $225.00 to $285.00 and gave the company an "overweight" rating in a report on Wednesday, July 29th. One research analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating and three have given a Hold rating to the company's stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and an average target price of $243.62.

Insider Activity

In other news, insider Eric Sherbet sold 5,000 shares of the firm's stock in a transaction on Wednesday, July 29th. The stock was sold at an average price of $249.16, for a total value of $1,245,800.00. Following the transaction, the insider directly owned 20,999 shares in the company, valued at $5,232,110.84. This trade represents a 19.23% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Bhavik Patel sold 1,855 shares of IQVIA stock in a transaction on Friday, July 31st. The stock was sold at an average price of $235.27, for a total value of $436,425.85. Following the sale, the insider directly owned 1,348 shares of the company's stock, valued at approximately $317,143.96. This trade represents a 57.91% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 15,581 shares of company stock worth $3,796,021. Corporate insiders own 1.70% of the company's stock.

IQVIA Stock Performance

Shares of NYSE:IQV opened at $267.34 on Tuesday. The company has a current ratio of 0.71, a quick ratio of 0.71 and a debt-to-equity ratio of 2.18. IQVIA Holdings Inc. has a 1-year low of $154.50 and a 1-year high of $271.80. The stock has a market capitalization of $44.00 billion, a P/E ratio of 33.17, a P/E/G ratio of 2.29 and a beta of 1.18. The business has a 50-day moving average price of $232.02 and a two-hundred day moving average price of $193.57.

IQVIA (NYSE:IQV - Get Free Report) last issued its earnings results on Tuesday, July 28th. The medical research company reported $3.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.03 by $0.12. The company had revenue of $4.37 billion for the quarter, compared to analyst estimates of $4.30 billion. IQVIA had a net margin of 8.10% and a return on equity of 30.25%. The company's revenue for the quarter was up 8.7% on a year-over-year basis. During the same quarter last year, the firm earned $2.81 EPS. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. Equities analysts predict that IQVIA Holdings Inc. will post 11.57 earnings per share for the current year.

IQVIA Profile

IQVIA NYSE: IQV is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA's principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.